Industry: Pharmaceuticals, Biotechnology
ProNAi Therapeutics, Inc. is a biopharmaceutical drug development company pioneering a new class of nucleic-acid drugs based on DNA interference (DNAi), which employs single strands of DNA to target and treat non-transcribed regions of genomes responsible for complex genetic diseases. ProNAi is currently developing multiple DNAi-based drug candidates with the potential to treat multiple cancers, including non-Hodgkin’s lymphoma, prostate, breast, and colon cancers. The company,s lead drug candidate, PNT-100, which has demonstrated in vivo efficacy in a variety of human tumor xenograft models, is currently in preclinical development. ProNAi is also exploring the potential of DNAi-based therapies for indications such as diabetes, Alzheimer,s and inflammatory ( www.pronai.com )
ProNAi Therapeutics , Inc.
Southwest Michigan Innovation Center 4717 Campus Drive Suite 1100
Kalamazoo, Michigan 49008
USA
Tel: (269) 372-3289
Fax: (269) 544-1079